Adnan Fazili

1 article listing Adnan Fazili in Nature Communications, indexed by Paperzzz from Crossref and OSF.

1. Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial Nature Communications